Coston McIsaac & Partners’s Edwards Lifesciences EW Stock Holding History

Coston McIsaac & Partners’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3K	Hold	36	–	–	﹤0.01%	731
2026 Q1	$2K	Hold	36	–	–	﹤0.01%	751
2025 Q4	$3K	Hold	36	–	–	﹤0.01%	711
2025 Q3	$2K	Hold	36	–	–	﹤0.01%	712
2025 Q2	$2K	Hold	36	–	–	﹤0.01%	690
2025 Q1	$2K	Hold	36	–	–	﹤0.01%	676
2024 Q4	$2K	Hold	36	–	–	﹤0.01%	676
2024 Q3	$2K	Hold	36	–	–	﹤0.01%	687
2024 Q2	$3K	Hold	36	–	–	﹤0.01%	626
2024 Q1	$3K	Sell	36 -12	-25%	-$1.01K	﹤0.01%	621
2023 Q4	$3K	Hold	48	–	–	﹤0.01%	619
2023 Q3	$3K	Hold	48	–	–	﹤0.01%	608
2023 Q2	$4K	Hold	48	–	–	﹤0.01%	624
2023 Q1	$3K	Hold	48	–	–	﹤0.01%	639
2022 Q4	$3K	Hold	48	–	–	﹤0.01%	642
2022 Q3	$3K	Hold	48	–	–	﹤0.01%	558
2022 Q2	$5K	Buy	+48	New	+$4.97K	﹤0.01%	341

Other funds holding EW

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

DZ Bank Frankfurt Am Main, Germany $130B AUM 46.38% 1-Year Est. Return

Ninety One (UK) London, United Kingdom $45.5B AUM 15.2% 1-Year Est. Return

Coston McIsaac & Partners's EW Position: Q2 2026 in Review

Coston McIsaac & Partners held its Edwards Lifesciences (EW) position steady in Q2 2026 at 36 shares worth $3K. The position accounts for ﹤0.01% of the portfolio, ranked #731.

Coston McIsaac & Partners first reported a position in EW in Q2 2022 and has held it in 17 quarters since. The position peaked at $5K in Q2 2022. 1,338 funds tracked by Wall St. Rank hold EW as of Q2 2026.

Coston McIsaac & Partners held 36 shares of Edwards Lifesciences worth $3K as of Q2 2026.
Coston McIsaac & Partners left its Edwards Lifesciences share count unchanged in Q2 2026.
Edwards Lifesciences made up ﹤0.01% of Coston McIsaac & Partners's portfolio in Q2 2026, its #731 holding.
Coston McIsaac & Partners first reported a position in Edwards Lifesciences in Q2 2022 and has held it in 17 quarters since.
Coston McIsaac & Partners's Edwards Lifesciences position peaked at $5K in Q2 2022.
1,338 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.

Based on Coston McIsaac & Partners's 13F filing for Q2 2026, filed 12 Aug 2026.